GeneTether Therapeutics (XCNQ:GTTX) ROCE % : -96.65% (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is GeneTether Therapeutics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. GeneTether Therapeutics's annualized ROCE % for the quarter that ended in Dec. 2023 was -96.65%.

GeneTether Therapeutics ROCE % Historical Data

The historical data trend for GeneTether Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GeneTether Therapeutics ROCE % Chart

GeneTether Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

ROCE %

-4,148.51

-171.29

-45.92

GeneTether Therapeutics Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial								-77.47	-49.36	-38.50	-11.70	-96.65

GeneTether Therapeutics ROCE % Calculation

GeneTether Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-1.002	/	( ( (2.641 - 0.118)	+	(1.893 - 0.052) )	/ 2 )
	=	-1.002	/	( (2.523	+	1.841)	/ 2 )
	=	-1.002	/	2.182
	=	-45.92 %

GeneTether Therapeutics's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-1.82	/	( ( (1.966 - 0.041)	+	(1.893 - 0.052) )	/ 2 )
	=	-1.82	/	( ( 1.925	+	1.841 )	/ 2 )
	=	-1.82	/	1.883
	=	-96.65 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

GeneTether Therapeutics (XCNQ:GTTX) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

GeneTether Therapeutics ROCE % Related Terms

Thank you for viewing the detailed overview of GeneTether Therapeutics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

GeneTether Therapeutics (XCNQ:GTTX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GeneTether Therapeutics Inc (XCNQ:GTTX) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

301-1665 Ellis Street, c/o Pushor Mitchell LLP, Kelowna, BC, CAN, V1Y 2B3

Website

https://www.genetether.com

GeneTether Therapeutics Inc is a genetic medicines company focused on the development of high-efficiency precision gene editing for human therapeutics applications. It is engaged in creating gene-editing therapies based on the proprietary GeneTether platform. Further, it is focused on building a discovery pipeline for the treatment of rare, monogenic diseases of the kidney and the skin.

GeneTether Therapeutics (XCNQ:GTTX) Headlines

No Headlines